Company Description

Outlook Therapeutics, formerly Oncobiologics, is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.